更多栏目
搜索
New Regulation Allows NDRL-Negotiated Drugs in Retail Pharmacies
储旻华·3月以前
PharmaDJ

Writer: Minhua Chu

Editor: Justin Fischer


On May 10, 2021, the National Healthcare Secruity Adminstration (NHSA) and National Health Commission (NHC) jointly released the “Guidelines on Establishing and Improving the ‘Double Channel’ Management Mechanism for Medicines on the NDRL Negotiation List”.


The so-called dual channel refers to the two sales channels for newly listed high-cost drugs through China’s National Drug Reimbursement List (NDRL). It means that patients can purchase certain drugs in designated retail pharmacies and the fees are covered by basic medical insurance (BMI). For the first time ever in China, sales channels outside of hospitals have are permitted to carry NDRL-negotiated drugs at the national level.


In recent years, several innovative drugs on the NDRL have rapidly progressed through the negotiation pathway. However, some patients have found that certain drugs are not available in hospitals. This is because the level of drug accessibility to the hospitals remains the same, while the frequency of NDRL negotiations has accelerated significantly.


Before reforms were introduced, innovative drugs were first channeled through hospitals and then listed on the NDRL. Now, this process is reveresed for many drugs. This change requires rapid access to hospitals in the short term. Because the negotiation period is two years, it is more likely to expire before even being introduced at a hospital.


The new regulation may help to alleviate this situation. Its purpose is to introduce flexible and widely-distributed services at designated retail pharmacies, put them into NDRL's supply of negotiated drugs, increase supply channels and improve accessibility.


The NHSA pointed out that it is up to the provincial healthcare security administration to decide which drugs are included in the dual channel system. It will implement the classification management for the negotiated drugs. Drugs in the dual channel should have high clincial value and be of urgent need. Alternative drugs will not be included in the dual channel.


Additionally, Good Pharmacovigilance Practices (GVP) was released on May 13. This is the first normative document for pharmacovigilance in China and a supporting document for the implementation of the newly revised Drug Administration Law.


gaitubao_图片3 (1).png
文章关键字: China Regulation Tracker GVP Good Pharmacovigilance Practices BMI basic medical insurance NDRL NHSA National Healthcare Secruity Adminstration NDRL-Negotiated Drugs Retail Pharmacies
483
谁阅读了此文章?
回复评论0
登录后回复评论,不超过1024个字(当前剩余字数:1024)
储旻华 个人用户

热衷收罗医药圈从研发到上市的各种“八卦”,然后基于事实和数据加以分析

联系方式

联系电话

电子邮箱

chu.minhua@pharmadj.com

公司名称

研发客

公司网站

公司地址

进入主页
Copyright © 2016-2021 研发客.All Rights Reserved.   建议反馈: Support@PharmaDJ.com   备案/许可证编号:沪ICP备17054709号-1   联系电话:021 - 88194359
关于研发客 | 加入会员 | 联系我们| 知识产权声明